leadf
logo-loader
viewMGC Pharmaceuticals Ltd
(
LSE:MXCOTC:MGCLFFRA:H5OASX:MXC
)

MGC Pharmaceuticals halted ahead of news on ArtemiC safety and toxicity pre-clinical study results

The company creates premium phytocannabinoid-based products from its GMP facility in Europe that can be used to treat patients suffering from a variety of symptomatic conditions.

MGC Pharmaceuticals Ltd - MGC Pharmaceuticals in in trading halt ahead of ArtemiC safety and toxicity pre-clinical study results
The halt is in place until Friday, July 24, or when an announcement is released to the market

MGC Pharmaceuticals Ltd (ASX:MXC) is in a trading halt ahead of an announcement in relation to safety and toxicity pre-clinical study results on AtremiC.

The trading halt will remain in place until the start of regular ASX trading on Friday, July 24, or when an announcement is released to the market, whichever occurs earliest.

Shares last traded at 2.4 cents and are up from 2 cents at the market close on July 1.

Move to acquire medicinal cannabis clinics

MGC Pharma this week announced that it intends acquiring 100% of the operating clinic-based assets, data and intellectual property of Medicinal Cannabis Clinic Pty Ltd (MCC). 

The company has signed a binding term sheet with Cannvalate Pty Ltd to acquire its wholly-owned subsidiary MCC.

As well as being one of Australia's leading medicinal cannabis clinics, MCC has an extensive doctor and patient network.

A new company will be incorporated to hold all the MCC assets which will be wholly-owned by MGC Pharma.

This would move MGC Pharma’s Australian supply chain to the new company, allowing the company to continue providing increasingly affordable cannabinoid medications though the focused reduction of importation, storage and distribution costs per unit.

Quick facts: MGC Pharmaceuticals Ltd

Follow
LSE:MXC

Price: 3.175 GBX

Market Cap: £75.72 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharmaceuticals: Continuous global breakthroughs as progress accelerates

Proactive Research Analyst Ed Stacey presents his analysis on MGC Pharmaceuticals (LON:MXC).  The company recently announced that it has received a UK import permit for CannEpil+, which is MGC’s cannabis-derived therapy for refractory epilepsy, to be used initially on a compassionate access...

1 week, 1 day ago

2 min read